Cancer cases are increasing due to medication

Cancer: price gouging with new drugs

Status: 03/08/2019 1:30 p.m. | archive
by Christine Seidemann and Sara Rainer
There is no price fixation for new drugs for one year after the market launch (topic picture).

The cost of new drugs has risen significantly in recent years. Again and again, cancer drugs have proven to be particularly expensive. The drug prescription report 2018 reveals that nine out of ten new developments in the oncological field cost more than 60,000 euros per year and patient in 2017. The rising costs put a heavy burden on the health insurance companies, announced the central association of statutory health insurance companies.

V.any new developments in oncology

In recent years, many new developments have been made in the field of oncology, which mean great progress for cancer patients. The Association of Research-Based Pharmaceutical Companies said that spending on cancer drugs that enable a cure or stop the disease and thus allow a return to normal life is not only an investment in the health of individual patients, but also in the interests of the health system a healthy investment for the entire economy.

Early launch for dGerman patient

The European Medicines Agency (EMA) approves new drugs for all of Europe at the same time. Nevertheless, German patients can often receive them faster than in neighboring countries. Because while there are intensive price negotiations following the approval, manufacturers in Germany can put their drugs on the market immediately and determine the price themselves. It is only in the second year that pharmaceutical companies and health insurance companies have to agree on a price. Price reductions of 50 percent are then not uncommon.

The price is only set in the second year

Experts complain not only that new drugs are expensive, but also that their actual benefit is often not yet apparent when they are approved. In Germany, a federal committee evaluates every newly approved drug. The Drug Ordinance Report 2018 shows: In nine out of ten new cancer drugs, the Federal Committee saw no evidence of additional benefit compared to older, cheaper drugs. The evaluation by the federal committee is the basis for price negotiations between pharmaceutical manufacturers and health insurance companies.

This topic in the program:

Market | 03/11/2019 | 8:15 pm